iPS commercialization, in vivo therapy enters the "era of governance"
Time：
2026-02-21 15:42
Author：
xieyijun
AI pharmaceuticals, entering the cash-in period
The new wave of AI pharmaceuticals
Time：
2026-02-20 23:32
Author：
xieyijun
When Milestone Payments Start to Materialize
Going Global: A New Era of Long-Termism
Time：
2026-02-19 12:21
Author：
xieyijun
Radiopharmaceuticals: Shedding the "Niche" Label
Treatment lines have been significantly moved forward.
Time：
2026-02-18 12:30
Author：
xieyijun
Johnson & Johnson: Marching Toward $100 Billion
A benchmark of diversification
Time：
2026-02-17 15:30
Author：
xieyijun
Hunting the Global "King of Autoimmune Diseases"
A cruel competition about "surpassing".
Time：
2026-02-15 21:41
Author：
xieyijun
FDA Launches Another Regulatory Onslaught
FDA Refuses to Review Moderna's Next-Generation mRNA Flu Vaccine
Time：
2026-02-15 08:18
Author：
xieyijun
When Pharmaceutical Giants Successively Replace Their CEOs
The First Move in Transformation: Turning Inward
Time：
2026-02-13 18:59
Author：
xieyijun
Recommended content
mRNA tumor vaccine "seller", entering a golden age
When a Biotech company that has been acquired achieves rare growth
AI、 Cold bench and puzzle, when will 'one person, one seedling' come to an end?
This road is long, but the threshold has already been crossed.
The "economic accounts" of immunology business development are being rewritten
After rejecting a $30 billion acquisition offer, a biotech company has emerged as a giant
determination for independence
联系我们
同写意
写意宣发
同写意Biotech
同写意微服务